Isbn: 9781119881339 - pharma and profits: balancing innovation, medicine, and drug prices (31 risultati)

Condizione: Very Good. Very Good condition. A copy that may have a few cosmetic defects. May also contain light spine creasing or a few markings such as an owner's name, short gifter's inscription or light stamp.

Condizione: good. Book shows wear from use but remains a usable copy. May include writing highlighting underlining library markings. LISTING USES STOCK PHOTOS AND COVER MAY VARY. Ships via USPS and typically arrives within 10-12 business days.

paperback. Condizione: Good. 1st Edition. Ships in a BOX from Central Missouri! May not include working access code. Will not include dust jacket. Has used sticker(s) and some writing or highlighting. UPS shipping for most packages, (Priority Mail for AK/HI/APO/PO Boxes).

Condizione: As New. Unread book in perfect condition.

Condizione: New.

Condizione: New.

Condizione: New. Brand New! Not Overstocks or Low Quality Book Club Editions! Direct From the Publisher! We're not a giant, faceless warehouse organization! We're a small town bookstore that loves books and loves it's customers! Buy from Lakeside Books.

Paperback or Softback. Condizione: New. Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Book.

Paperback. Condizione: New. High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include: Fiscal consequences of curing hepatitis CmRNA vaccines and the race for a cureWhy the government does not deserve a piece of Biopharma's profitsPaying for drugs whose ultimate value is unknownThe impact of reduced revenues on RandDThis book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry. …

Condizione: New.

Paperback. Condizione: New. High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include: Fiscal consequences of curing hepatitis CmRNA vaccines and the race for a cureWhy the government does not deserve a piece of Biopharma's profitsPaying for drugs whose ultimate value is unknownThe impact of reduced revenues on RandDThis book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry. …

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Condizione: new.

Condizione: New.

Condizione: New. 2022. 1st Edition. Paperback. . . . . .

Condizione: New.

Condizione: New. In English.

Condizione: As New. Unread book in perfect condition.

Condizione: New.

Paperback. Condizione: New.

Condizione: New. 2022. 1st Edition. Paperback. . . . . . Books ship from the US and Ireland.

Paperback / softback. Condizione: New. New copy - Usually dispatched within 4 working days.

Paperback. Condizione: New. Special order direct from the distributor.

Condizione: New. Brand new! Please provide a physical shipping address.

Paperback. Condizione: New. High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include: Fiscal consequences of curing hepatitis CmRNA vaccines and the race for a cureWhy the government does not deserve a piece of Biopharma's profitsPaying for drugs whose ultimate value is unknownThe impact of reduced revenues on RandDThis book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry. …

Kartoniert / Broschiert. Condizione: New. John LaMattina, PhD is the former Senior Vice President, Pfizer Inc and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe .

Taschenbuch. Condizione: Neu. Neuware - High-level commentary on various facets of the pharmaceutical industry from a key leader in the fieldThis book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:\* Fiscal consequences of curing hepatitis C\* mRNA vaccines and the race for a cure\* Why the government does not deserve a piece of Biopharma's profits\* Paying for drugs whose ultimate value is unknown\* The impact of reduced revenues on R&DThis book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.…

Paperback. Condizione: New. High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include: Fiscal consequences of curing hepatitis CmRNA vaccines and the race for a cureWhy the government does not deserve a piece of Biopharma's profitsPaying for drugs whose ultimate value is unknownThe impact of reduced revenues on RandDThis book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry. …

Paperback. Condizione: Brand New. 100 pages. 9.00x6.00x0.25 inches. In Stock. This item is printed on demand.

Condizione: New. PRINT ON DEMAND.